Avacta Group Past Earnings Performance
Past criteria checks 0/6
Avacta Group's earnings have been declining at an average annual rate of -27.6%, while the Biotechs industry saw earnings growing at 19.7% annually. Revenues have been growing at an average rate of 43.4% per year.
Key information
-27.6%
Earnings growth rate
-8.8%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 43.4% |
Return on equity | -114.4% |
Net Margin | -107.3% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Avacta Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 23 | -25 | 20 | 15 |
30 Sep 23 | 20 | -32 | 21 | 13 |
30 Jun 23 | 16 | -42 | 22 | 11 |
31 Mar 23 | 13 | -41 | 20 | 11 |
31 Dec 22 | 10 | -37 | 19 | 11 |
30 Sep 22 | 8 | -31 | 17 | 12 |
30 Jun 22 | 7 | -25 | 15 | 13 |
31 Mar 22 | 5 | -26 | 14 | 13 |
31 Dec 21 | 3 | -26 | 13 | 13 |
30 Jun 21 | 2 | -20 | 9 | 12 |
31 Mar 21 | 2 | -18 | 9 | 10 |
31 Dec 20 | 2 | -16 | 9 | 9 |
30 Jun 20 | 5 | -12 | 8 | 7 |
31 Mar 20 | 4 | -12 | 8 | 6 |
31 Dec 19 | 4 | -11 | 7 | 6 |
31 Jul 19 | 4 | -10 | 8 | 6 |
30 Apr 19 | 3 | -10 | 8 | 5 |
31 Jan 19 | 2 | -10 | 8 | 5 |
31 Oct 18 | 3 | -9 | 8 | 4 |
31 Jul 18 | 3 | -9 | 7 | 3 |
30 Apr 18 | 3 | -8 | 7 | 3 |
31 Jan 18 | 3 | -7 | 8 | 3 |
31 Oct 17 | 3 | -7 | 7 | 3 |
31 Jul 17 | 3 | -6 | 7 | 3 |
30 Apr 17 | 3 | -6 | 7 | 2 |
31 Jan 17 | 2 | -6 | 7 | 2 |
31 Oct 16 | 2 | -5 | 6 | 2 |
31 Jul 16 | 2 | -5 | 5 | 2 |
30 Apr 16 | 2 | -5 | 5 | 1 |
31 Jan 16 | 2 | -5 | 5 | 0 |
31 Oct 15 | 2 | -5 | 4 | 0 |
31 Jul 15 | 2 | -5 | 4 | 0 |
30 Apr 15 | 2 | -4 | 4 | 0 |
31 Jan 15 | 2 | -3 | 4 | 0 |
31 Oct 14 | 2 | -2 | 3 | 0 |
31 Jul 14 | 2 | -1 | 3 | 0 |
30 Apr 14 | 2 | -1 | 3 | 0 |
31 Jan 14 | 2 | -1 | 3 | 0 |
31 Oct 13 | 3 | -1 | 3 | 0 |
Quality Earnings: AVCT.F is currently unprofitable.
Growing Profit Margin: AVCT.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AVCT.F is unprofitable, and losses have increased over the past 5 years at a rate of 27.6% per year.
Accelerating Growth: Unable to compare AVCT.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AVCT.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: AVCT.F has a negative Return on Equity (-114.41%), as it is currently unprofitable.